검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Rilvegostomig (AZD8205 and AZD2936, AZD8205 and AZD2936 (Rilvegostomig)) AstraZeneca·Breast Cancer 30 trials |
|---|---|
Overview Program | AZD8205 and AZD2936 (Rilvegostomig) |
Overview Company | AstraZeneca |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Biliary Tract Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting both PD-1 and TIGIT receptor |
MoA Biomarker | biomarker strategies to identify high-risk patients who may benefit from adjuvant treatment |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.. We evaluated the activity of AZD8205, a B7-H4-directed antibody-drug conjugate (ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination with the PARP1-selective inhibitor AZD5305, in preclinical models. … |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Rilvegostomig (AZD8205 and AZD2936, AZD8205 and AZD2936 (Rilvegostomig)) AstraZeneca·Breast Cancer 30 trials |
|---|---|
Overview Program | AZD8205 and AZD2936 (Rilvegostomig) |
Overview Company | AstraZeneca |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Biliary Tract Carcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting both PD-1 and TIGIT receptor |
MoA Biomarker | biomarker strategies to identify high-risk patients who may benefit from adjuvant treatment |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.. We evaluated the activity of AZD8205, a B7-H4-directed antibody-drug conjugate (ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination with the PARP1-selective inhibitor AZD5305, in preclinical models. … |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교